Navigation Links
CMC Biologics Announces Agreement With Daiichi Sankyo Company to Develop and Manufacture Antibodies
Date:10/26/2011

SEATTLE and COPENHAGEN, Denmark, Oct. 26, 2011 /PRNewswire/ -- CMC Biologics today announced the execution of an agreement with Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') to provide process development support and manufacture of several clinical-stage antibodies over a three-year period. The two companies have recently begun work on their first joint project at CMC Biologics' Bothell manufacturing facility. Specific terms of the agreement were not disclosed.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"CMC Biologics is delighted to partner with Daiichi Sankyo, a leader among pharmaceutical companies worldwide with a heritage of scientific discovery that spans more than one hundred years," noted Gustavo F. Mahler, Ph.D., Global Chief Operations Officer at CMC Biologics. "We will be working closely with Daiichi Sankyo on the development and production of antibodies over the next several years."

Junichi Koga, Ph.D., Vice President, Biopharmaceutical Technology Research Laboratories at Daiichi Sankyo, commented, "I believe CMC Biologics is the best partner for Daiichi Sankyo because of their depth of experience and excellent quality. Together we have created a responsive working relationship to bring best-in-class biologics to patients in need."

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

About CMC Biologics

CMC Biologics (www.cmcbio.com) is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.


'/>"/>
SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma.
2. Senator Menendez, Lt. Governor Guadagno Unveil New Biotech Firm Oncobiologics
3. Oncobiologics, Inc. Announces Two New Agreements Worth Close to $80 Million
4. ProteinSimple to Offer Direct Sales, Service and Support for Biologics Products in Europe
5. Director of Commerce, Rogers Weed, Presided Over Ribbon Cutting Ceremony Celebrating Opening of Expanded Manufacturing Facility at CMC Biologics
6. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
7. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
8. Aperion Biologics Invited to Present at the UBS Global Life Sciences Conference
9. CMC Biologics Adds 2,000 Liter Single-Use Bioreactor at its Copenhagen Manufacturing Facility
10. Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform
11. Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... KEY FINDINGS Patient warming ... reducing loss of blood during surgeries, lowering the ... recovery after surgeries, and decreasing risks of SSIs. ... convective warming system, surface warming systems, and intravascular ... stay at hospitals thus, lowering the healthcare costs ...
(Date:12/7/2016)... 7, 2016 Global Hospital Linen Supply and ... global hospital linen supply and management services market presents ... a global and regional level. The study provides historic ... between 2015 and 2024 based on revenue (US$ Bn). ... market along with their impact on demand during the ...
(Date:12/7/2016)... N.J. , Dec. 7, 2016  Palatin ... it has closed on a previously disclosed underwritten ... $16,500,000.  Canaccord Genuity acted as sole book-running manager, ... Chardan Capital Markets acted as co-manager for the ... approximately $15.4 million in net proceeds, allowing us ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes ... and around the nation. What do they have in common? All have been affected ... compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... promoting to the US market its advanced highly customizable contact technology solutions. , ... TURNTAC®. These advanced technologies are ideal for a wide range of applications that ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers ... to residents in the Sacramento/Folsom region, is initiating a charity event to raise ... Another Choice Another Chance treatment center in Sacramento works to provide area teens ...
(Date:12/7/2016)... , ... December 07, 2016 , ... One of two ... of the securement tape is painful for her. "This is why the co-inventor and ... heads," she said. , They then created a prototype of the patent-pending AV-AIR, a ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a ... throughout the Five Boroughs, is launching a charity drive to raise funds that will ... traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the MCL, ...
Breaking Medicine News(10 mins):